Screening for Familial APP Mutations in Sporadic Cerebral Amyloid Angiopathy

DSpace/Manakin Repository

Screening for Familial APP Mutations in Sporadic Cerebral Amyloid Angiopathy

Show simple item record

dc.contributor.author Plourde, Anna
dc.contributor.author Onofrio, Robert
dc.contributor.author Prada, Claudia M.
dc.contributor.author Biffi, Alessandro
dc.contributor.author Shen, Yiping
dc.contributor.author Smith, Eric E.
dc.contributor.author Frosch, Matthew P.
dc.contributor.author Gusella, James Francis
dc.contributor.author Greenberg, Steven Mark
dc.contributor.author Rosand, Jonathan
dc.date.accessioned 2011-04-29T02:02:00Z
dc.date.issued 2010
dc.identifier.citation Biffi, Alessandro, Anna Plourde, Yiping Shen, Robert Onofrio, Eric E. Smith, Matthew Frosch, Claudia M. Prada, James Gusella, Steven M. Greenberg, and Jonathan Rosand. 2010. Screening for Familial APP Mutations in Sporadic Cerebral Amyloid Angiopathy. PLoS ONE 5(11): e13949. en_US
dc.identifier.issn 1932-6203 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4879200
dc.description.abstract Background: Advances in genetic technology have revealed that variation in the same gene can cause both rare familial and common sporadic forms of the same disease. Cerebral amyloid angiopathy (CAA), a common cause of symptomatic intracerebral hemorrhage (ICH) in the elderly, can also occur in families in an autosomal dominant pattern. The majority of affected families harbor mutations in the Beta amyloid Peptide (Aβ) coding region of the gene for amyloid precursor protein (APP) or have duplications of chromosomal segments containing APP. Methodology/Principal Findings: A total of 58 subjects with a diagnosis of probable or definite CAA according to validated criteria were included in the present study. We sequenced the Aβ coding region of APP in 58 individuals and performed multiplex ligation-dependent probe amplification to determine APP gene dosage in 60. No patient harbored a known or novel APP mutation or gene duplication. The frequency of mutations investigated in the present study is estimated to range from 0% to 8% in individuals with probable CAA in the general population, based on the ascertained sample size. Conclusions/Significance: We found no evidence that variants at loci associated with familial CAA play a role in sporadic CAA. Based on our findings, these rare highly-penetrant mutations are unlikely to be seen in sporadic CAA patients. Therefore, our results do not support systematic genetic screening of CAA patients who lack a strong family history of hemorrhage or dementia. en_US
dc.language.iso en_US en_US
dc.publisher Public Library of Science en_US
dc.relation.isversionof doi:10.1371/journal.pone.0013949 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978718/pdf/ en_US
dash.license LAA
dc.subject genetics and genomics en_US
dc.subject complex traits en_US
dc.subject genetics of disease en_US
dc.subject neurological disorders en_US
dc.subject cerebrovascular disease en_US
dc.subject neurogenetics en_US
dc.title Screening for Familial APP Mutations in Sporadic Cerebral Amyloid Angiopathy en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal PLoS ONE en_US
dash.depositing.author Gusella, James Francis
dc.date.available 2011-04-29T02:02:00Z
dash.affiliation.other HMS^Genetics en_US

Files in this item

Files Size Format View
2978718.pdf 74.51Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters